429 related articles for article (PubMed ID: 15251125)
1. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
2. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
3. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
4. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
5. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
6. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
7. Modulation of TRAIL signaling for cancer therapy.
Fulda S; Debatin KM
Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
[TBL] [Abstract][Full Text] [Related]
8. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.
Cillessen SA; Meijer CJ; Ossenkoppele GJ; Castricum KC; Westra AH; Niesten P; Muris JJ; Nijdam HF; van der Hem KG; Flens M; Hooijberg E; Oudejans JJ
Br J Haematol; 2006 Aug; 134(3):283-93. PubMed ID: 16848771
[TBL] [Abstract][Full Text] [Related]
9. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
10. Tumor therapeutics by design: targeting and activation of death receptors.
Wajant H; Gerspach J; Pfizenmaier K
Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
[TBL] [Abstract][Full Text] [Related]
11. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
12. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.
Shankar S; Srivastava RK
Drug Resist Updat; 2004 Apr; 7(2):139-56. PubMed ID: 15158769
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
15. TRAIL and malignant glioma.
Hawkins CJ
Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
[TBL] [Abstract][Full Text] [Related]
16. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
17. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
18. Apo2L/TRAIL and its death and decoy receptors.
LeBlanc HN; Ashkenazi A
Cell Death Differ; 2003 Jan; 10(1):66-75. PubMed ID: 12655296
[TBL] [Abstract][Full Text] [Related]
19. Safety and antitumor activity of recombinant soluble Apo2 ligand.
Ashkenazi A; Pai RC; Fong S; Leung S; Lawrence DA; Marsters SA; Blackie C; Chang L; McMurtrey AE; Hebert A; DeForge L; Koumenis IL; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall RH
J Clin Invest; 1999 Jul; 104(2):155-62. PubMed ID: 10411544
[TBL] [Abstract][Full Text] [Related]
20. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
